C07C315/04

Racemic beta-aminosulfone compounds

It is described an industrially viable and advantageous process for the preparation of racemic beta-aminosulfone (1), an useful intermediate for the preparation of N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)acetamide, also known as Apremilast, the latter being suitable for use in methods of treating, preventing and/or managing psoriasis or psoriatic arthritis.

NEW CYCLOADDUCT PRECURSORS OF DIHALODIPHENYLSULFONES AND PREPARATIONS THEREOF
20200190102 · 2020-06-18 ·

The invention relates to new compounds of formula (I) wherein X represents a halogen atom selected from the group consisting of fluorine, chlorine, bromine and iodine, which are useful for the preparation of 4,4dihalodiphenylsulfones of formula (III) wherein X is as defined above.

##STR00001##

NEW CYCLOADDUCT PRECURSORS OF DIHALODIPHENYLSULFONES AND PREPARATIONS THEREOF
20200190102 · 2020-06-18 ·

The invention relates to new compounds of formula (I) wherein X represents a halogen atom selected from the group consisting of fluorine, chlorine, bromine and iodine, which are useful for the preparation of 4,4dihalodiphenylsulfones of formula (III) wherein X is as defined above.

##STR00001##

NEW CYCLOADDUCT PRECURSORS OF DIHALODIPHENYLSULFONES AND PREPARATIONS THEREOF
20200190102 · 2020-06-18 ·

The invention relates to new compounds of formula (I) wherein X represents a halogen atom selected from the group consisting of fluorine, chlorine, bromine and iodine, which are useful for the preparation of 4,4dihalodiphenylsulfones of formula (III) wherein X is as defined above.

##STR00001##

ROR GAMMA (RORy) MODULATORS

The present application relates to compounds according to (Formula IA) or (Formula IB):

##STR00001## or a pharmaceutically acceptable salt thereof.

The compounds can be used as inhibitors of ROR and are useful for the treatment of ROR mediated diseases.

ROR GAMMA (RORy) MODULATORS

The present application relates to compounds according to (Formula IA) or (Formula IB):

##STR00001## or a pharmaceutically acceptable salt thereof.

The compounds can be used as inhibitors of ROR and are useful for the treatment of ROR mediated diseases.

Process for the preparation of arylsulfonylpropenenitriles by photocatalytic reactions

A process for a preparation of arylsulfonylpropenenitriles is disclosed. A reaction starting from arylsulfonyl iodides is catalyzed by light. The process is scalable, environmentally benign and provides the product in good yield.

Process for the preparation of arylsulfonylpropenenitriles by photocatalytic reactions

A process for a preparation of arylsulfonylpropenenitriles is disclosed. A reaction starting from arylsulfonyl iodides is catalyzed by light. The process is scalable, environmentally benign and provides the product in good yield.

Process for the preparation of arylsulfonylpropenenitriles by photocatalytic reactions

A process for a preparation of arylsulfonylpropenenitriles is disclosed. A reaction starting from arylsulfonyl iodides is catalyzed by light. The process is scalable, environmentally benign and provides the product in good yield.

SOLID STATE FORMS OF N-[2-[(I S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF

The present invention, relates to solid state forms of N-[2-[(1 S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide represented by the following structural formula-1 and process for their preparation. The present invention also relates to an improved process for the preparation of N-[2-[(1 S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide compound of formula-1 and intermediates thereof.